ORASURE TECHNOLOGIES INC 8-K

What Happened OraSure Technologies, Inc. (OSUR) reported on June 11, 2026 (Item 8.01) that the U.S. Food and Drug Administration cleared its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc., for use with Roche Molecular Systems tests. The clearance covers detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche’s cobas® 5800, 6800, and 8800 molecular diagnostic systems and supports at‑home self‑collection of first‑void urine for male and female patients.

Key Details

• Filing date: June 11, 2026 (Form 8-K, Item 8.01).
• Product: Colli-Pee™•Dx Urine Collection Kit (DNA Genotek subsidiary).
• Cleared uses: For Roche tests detecting C. trachomatis, N. gonorrhoeae, T. vaginalis, and M. genitalium.
• Instrument compatibility: Roche cobas® 5800, 6800, and 8800 systems; supports at‑home first‑void urine self‑collection for both sexes.

Why It Matters The company disclosed a regulatory clearance that authorizes its at‑home urine collection kit for use with widely used Roche molecular tests and instruments. The filing states the clearance enables convenient at‑home sample collection for male and female patients. This is a regulatory development rather than a financial disclosure; investors should note the announcement does not include revenue or sales guidance.